Cellectis SA (CLLS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cellectis SA stock (CLLS) is currently trading at $3.23. Cellectis SA PS ratio (Price-to-Sales) is 4.07. Analyst consensus price target for CLLS is $7.25. WallStSmart rates CLLS as Sell.
- CLLS PE ratio analysis and historical PE chart
- CLLS PS ratio (Price-to-Sales) history and trend
- CLLS intrinsic value — DCF, Graham Number, EPV models
- CLLS stock price prediction 2025 2026 2027 2028 2029 2030
- CLLS fair value vs current price
- CLLS insider transactions and insider buying
- Is CLLS undervalued or overvalued?
- Cellectis SA financial analysis — revenue, earnings, cash flow
- CLLS Piotroski F-Score and Altman Z-Score
- CLLS analyst price target and Smart Rating
Cellectis SA
📊 No data available
Try selecting a different time range
Smart Analysis
Cellectis SA (CLLS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth. Concerns around return on equity and profit margin. Significant fundamental concerns warrant caution or avoidance.
Cellectis SA (CLLS) Key Strengths (2)
Revenue surging 105.90% year-over-year
Strong operational efficiency: $22 kept per $100 revenue
Supporting Valuation Data
Cellectis SA (CLLS) Areas to Watch (6)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Premium valuation at 4.1x annual revenue
Premium pricing at 3.3x book value
Low institutional interest, mostly retail-driven
Small-cap company with higher risk but more growth potential
Cellectis SA (CLLS) Detailed Analysis Report
Overall Assessment
This company scores 35/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Operating Margin. Profitability is solid with Operating Margin at 21.60%. Growth metrics are encouraging with Revenue Growth at 105.90%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Price/Sales. Some valuation metrics including Price/Sales (4.07), Price/Book (3.34) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -30.70%, Profit Margin at -42.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -30.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 105.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CLLS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CLLS's Price-to-Sales ratio of 4.07x trades at a deep discount to its historical average of 55.95x (12th percentile). The current valuation is 99% below its historical high of 285.56x set in Jan 2024, and 98% above its historical low of 2.06x in Dec 2022. Over the past 12 months, the PS ratio has expanded from ~2.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cellectis SA (CLLS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Cellectis SA is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 83M with 106% growth year-over-year. The company is currently unprofitable, posting a -42.8% profit margin.
Key Findings
Revenue growing at 106% YoY, reaching 83M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 30% of revenue (24M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -42.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -43M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Cellectis SA maintain 106%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.85, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Cellectis SA.
Bottom Line
Cellectis SA is a high-conviction growth story with revenue accelerating at 106% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -42.8% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:23:18 AM
About Cellectis SA(CLLS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.